Contraindications and Risk Factors Certain individuals may not be suitable candidates for GLP-1 therapy
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
Both acarbose and voglibose are effective in controlling postprandial blood glucose levels, with no significant difference in control
Chuansangeam M, Phadungsaksawasdi P, Park HJ, Yang YH (2025) Exploring the link between GLP-1 receptor agonists and dementia: A comprehensive review
Medvi primarily offers online medical weight-loss care, with access to prescription treatments, including GLP-1 options for those who qualify
B., & Wadden, T
